


Tackling inequities in access to cancer prevention, early detection & treatment by rural women: Case of Cervical Cancer

Chemtai Mungo, MD, MPH, FACOG
Assistant Professor, Obstetrics and Gynecology
WHO Seminar, Feb 24th 2022


No disclosures

Cervical cancer – disparities in mortality from a preventable disease

(Map shows countries sized by number of cervical cancer deaths. Numbers represent age-standardized mortality rates.)



The Development of Cervical Cancer



Typical timespan from HPV infection to cancer: 10-30 years

- Preventable
- Primary & secondary prevention
- 570,000 cases annually, 90% in LMICs
- Rural women bear highest burden

2018: WHO Call for Cervical Cancer Elimination

THE ARCHITECTURE TO ELIMINATE CERVICAL CANCER:

VISION: A world without cervical cancer

THRESHOLD: All countries to reach < 4 cases 100,000 women-years

2030 CONTROL TARGETS

90%

of girls fully vaccinated with HPV vaccine by 15 years of age 70%

of women screened with an high precision test at 35 and 45 years of age 90%

of women identified with cervical disease receive treatment and care

SDG 2030: Target 3.4 – 30% reduction in mortality from cervical cancer

The 2030 targets and elimination threshold are subject to revision depending on the outcomes of the modeling and the WHO approval process





Dr Tedros Adhanom GhebreyesusWHO Director - General

Tools:

- HPV vaccine
- POC HPV tests, self-sampling
- Same-day treatment of precancer

Primary Prevention: HPV Vaccination





- 2020: Only 31% of countries in SSA had national HPV vaccination programs
- School-based programs impacted by Covid-19 pandemic, vaccine supplies
- New evidence for 1-dose, increase access


Secondary Prevention: Screening and treatment of cervical precancer



- Unlike high-income countries, services offered by non-physicians
- Screen & treat: Fewer visits, couple screening with same-day treatment
- Move screening & treatment from hospitals/tertiary centers and closer to rural communities

HPV Self-Collection for Screening





- HPV test endorsed by WHO as first-line
- Ideal for self-sampling
- Community or home-based screening
- Point of care tests: Same day results
- Accurate multiple studies
- Acceptable
- Cost-effective

HPV Self-Collection: highly acceptable

- Jeronimo et al (2017) women prefer self-collection
- 20,461 women enrolled in study

	Nicaragua	Hyderabad	Uganda	Delhi	Total
% of women who provided vaginal sample	86.8	80.7	99.5	99.4	91.3

Community-based HPV screening



- Increased access vs facility-based care
- Use of HPV self-sampling
- Cost-effective: part of multi-disease campaign
- Linkage to treatment: immediate vs facility-based


Treatment of precancerous lesions: Use of portable devices






WHO, 2019

Access: Moving from policy to practice





- Many LMICs endorsed WHO Elimination agenda
- Ensure high coverage of screening & treatment in rural areas – still mostly focused in urban areas
- Digital innovations can bridge gaps
- Address health workforce shortages in remote clinics
- Linkage to tertiary care key
- Advocacy and accountability



THE UNIVERSITY

of NORTH CAROLINA

at CHAPEL HILL